We invite individuals with a strong background neuroscience, neurodegenerative disease, Alzheimer’s disease, and/or traumatic brain injury research to inquire about joining our highly multidisciplinary program focused on blast-related mild traumatic brain injury (mTBI) at the VA Medical Center and University of Washington in Seattle, WA.
We are working to understand the underlying mechanisms whereby repetitive mTBI develops into chronic behavioral, cognitive, and neuropathological disorders. Our highly interdisciplinary team of basic and clinical scientists is working on several interwoven approaches and questions:
Battlefield and translationally relevant animal modeling of blast-induced mTBI and AD models.
Impact of sleep deprivation on susceptibility to mild traumatic brain injury.
Multi-modal neuroimaging (PET, DTI, resting and task-based functional MRI, MPF) in Veterans with blast-related mTBI.
Neuroimaging of blast and impact mTBI exposed animals (PET, DTI).
In-depth neuropathology in blast-exposed animals AND in rare human blast-related postmortem cases.
Real-time in vivo two photon imaging in animal mTBI models.
Real-time in vivo dopamine release using fast-scan voltametry in mice.
Electrophysiological approaches examining of blast-induced mTBI
In-depth investigations of the complex behavioral and cognitive impairments displayed by Veterans with blast-related mTBI and their relationship to neurodegenerative disease, including Alzheimer’s disease.
Plasma and CSF mTBI biomarkers (protein, microRNAs, exosomes).
State-of-the-art light sheet microscopy.
PhD, MD, or PhD is required.
United States Citizenship is required.
Strong background in neuroscience.
Expertise in molecular-focused animal model studies is desirable.
Internal Number: 123456
About University of Washington / VAPSHCS
This is an inter-disciplinary molecular, neuroimaging, intravital imaging, neurocognitive, biomarker, and clinical research group focused on understanding and preventing blast-induced mild traumatic brain injury (mTBI) from progressing to chronic neurodegenerative disease.